MX384199B - Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. - Google Patents

Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.

Info

Publication number
MX384199B
MX384199B MX2017014955A MX2017014955A MX384199B MX 384199 B MX384199 B MX 384199B MX 2017014955 A MX2017014955 A MX 2017014955A MX 2017014955 A MX2017014955 A MX 2017014955A MX 384199 B MX384199 B MX 384199B
Authority
MX
Mexico
Prior art keywords
immunoreceptor
tigit
domains
binding agents
based inhibition
Prior art date
Application number
MX2017014955A
Other languages
English (en)
Other versions
MX2017014955A (es
Inventor
Austin L Gurney
Ming-Hong Xie
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2017014955A publication Critical patent/MX2017014955A/es
Publication of MX384199B publication Critical patent/MX384199B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a agentes que unen específicamente TIGIT. Los agentes de unión de TIGIT pueden incluir polipéptidos, anticuerpos, y/o agentes biespecíficos. También se describen métodos para usar los agentes para mejorar la respuesta inmunitaria y/o tratamiento de enfermedades tal como cáncer.
MX2017014955A 2015-05-28 2016-05-27 Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos. MX384199B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562167582P 2015-05-28 2015-05-28
US201562205279P 2015-08-14 2015-08-14
US201662313487P 2016-03-25 2016-03-25
PCT/US2016/034549 WO2016191643A2 (en) 2015-05-28 2016-05-27 Tigit-binding agents and uses thereof

Publications (2)

Publication Number Publication Date
MX2017014955A MX2017014955A (es) 2018-04-13
MX384199B true MX384199B (es) 2025-03-14

Family

ID=57393726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014955A MX384199B (es) 2015-05-28 2016-05-27 Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.

Country Status (31)

Country Link
US (2) US10112997B2 (es)
EP (2) EP4011907A1 (es)
JP (2) JP6875295B2 (es)
KR (1) KR102721641B1 (es)
CN (2) CN109071620B (es)
AU (1) AU2016267577B2 (es)
BR (1) BR112017025529A2 (es)
CA (1) CA2987607A1 (es)
CL (1) CL2017003021A1 (es)
CO (1) CO2017012342A2 (es)
CY (1) CY1125260T1 (es)
DK (1) DK3303379T3 (es)
EC (1) ECSP17083779A (es)
ES (1) ES2902150T3 (es)
HR (1) HRP20211948T1 (es)
HU (1) HUE057087T2 (es)
IL (1) IL255577B (es)
LT (1) LT3303379T (es)
MA (1) MA42622B1 (es)
MD (1) MD3303379T2 (es)
MX (1) MX384199B (es)
NZ (1) NZ738008A (es)
PL (1) PL3303379T3 (es)
PT (1) PT3303379T (es)
RS (1) RS62815B1 (es)
SA (1) SA517390370B1 (es)
SI (1) SI3303379T1 (es)
SM (1) SMT202100711T1 (es)
TW (1) TWI715587B (es)
WO (1) WO2016191643A2 (es)
ZA (1) ZA201708265B (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011088A (es) 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102050082B1 (ko) 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
DK3259597T3 (da) 2015-02-19 2022-05-09 Compugen Ltd Pvrig-polypeptider og fremgangsmåder til behandling
CA2976926A1 (en) 2015-02-19 2016-08-25 Compugen Ltd. Anti-pvrig antibodies and methods of use
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
US10894823B2 (en) 2016-03-24 2021-01-19 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MA45123A (fr) 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
IL301682B2 (en) * 2016-08-17 2025-06-01 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
US11230596B2 (en) * 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
JP7118072B2 (ja) * 2017-01-06 2022-08-15 イミュニティーバイオ インコーポレイテッド Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞
MA47694A (fr) * 2017-02-28 2021-05-19 Seagen Inc Anticorps anti-tigit
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
CA3054068A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JOP20190203A1 (ar) * 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
TW202402800A (zh) * 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
CN110799213A (zh) 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
CA3070100A1 (en) * 2017-07-17 2019-01-24 Janssen Biotech, Inc. Antigen binding regions against fibronectin type iii domains and methods of using the same
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
BE1025333B1 (fr) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. Anticorps anti-tigit
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa ANTI-TIGIT ANTIBODIES
EP3689909A4 (en) * 2017-09-29 2021-12-29 Jiangsu Hengrui Medicine Co., Ltd. Tigit antibody, antigen-binding fragment thereof, and medical use thereof
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
EP3697435A1 (en) * 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3735417A1 (en) * 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN111601826B (zh) * 2018-01-15 2023-12-15 南京传奇生物科技有限公司 针对tigit的抗体及其变体
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
AU2019256539A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
AU2019310803B2 (en) * 2018-07-25 2022-11-03 Innovent Biologics (Suzhou) Co., Ltd. Anti-TIGIT antibody and uses thereof
AU2019324170A1 (en) 2018-08-23 2021-02-18 Seagen, Inc. Anti-TIGIT antibodies
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
CA3123338A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
CN113993894B (zh) * 2019-01-07 2024-08-02 Iteos比利时公司 抗tigit抗体
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20220146500A1 (en) * 2019-02-27 2022-05-12 Yale University Compositions and methods for enhancing mucosal immunity
WO2020185739A1 (en) 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用
TWI760751B (zh) 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
BR112021022171A2 (pt) * 2019-06-13 2021-12-21 Green Cross Corp Anticorpo para tigit, seu uso e método para produzir o mesmo
AU2020298324A1 (en) * 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
US20220267475A1 (en) * 2019-06-25 2022-08-25 Nanjing GenScript Biotech Co., Ltd. Anti-cd47/anti-tigit bispecific antibody, preparation method therefor and application thereof
WO2020263312A1 (en) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
US20220363754A1 (en) * 2019-07-15 2022-11-17 Shanghai Junshi Biosciences Co., Ltd. Anti-tigit antibodies and application thereof
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN110669139B (zh) * 2019-09-18 2025-12-02 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
JP7122354B2 (ja) * 2019-09-24 2022-08-19 財團法人工業技術研究院 抗ｔｉｇｉｔ抗体および使用方法
WO2021062332A1 (en) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer
CA3157024A1 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021091960A1 (en) 2019-11-05 2021-05-14 Jounce Therapeutics, Inc. Methods of treating cancer with anti-pd-1 antibodies
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
TW202136287A (zh) 2019-12-17 2021-10-01 法商Ｏｓｅ免疫治療公司 包含il-7變體之雙官能分子
WO2021139776A1 (en) * 2020-01-10 2021-07-15 Shanghai Henlius Biotech, Inc. Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
CN112409450B (zh) * 2020-03-29 2023-01-24 郑州大学 TIGIT-IgV的亲和剂及其应用
CN113563470B (zh) 2020-04-29 2023-02-10 广州昂科免疫生物技术有限公司 结合tigit抗原的抗体及其制备方法与应用
JP2023525082A (ja) 2020-05-07 2023-06-14 アンスティテュ・クリー 免疫抑制線維芽細胞集団のバイオマーカーとしてのａｎｔｘｒ１及び免疫療法に対する応答を予測するためのその使用
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells
CR20220611A (es) 2020-06-02 2023-06-07 Arcus Biosciences Inc Anticuerpos anti-tigit
WO2021258337A1 (en) * 2020-06-24 2021-12-30 Huahui Health Ltd. Human monoclonal antibodies against tigit for immune related diseases
MX2023000197A (es) 2020-07-07 2023-02-22 BioNTech SE Arn terapeutico para el cancer positivo para vph.
CN111763660A (zh) * 2020-08-07 2020-10-13 南京大学 一种重组溶瘤痘苗病毒及其制备方法和应用
CN112190689B (zh) * 2020-08-25 2022-12-09 沣潮医药科技（上海）有限公司 Tigit免疫粘附素在调控肿瘤免疫及调节血管生成产品中的应用
CA3194641A1 (en) * 2020-10-26 2022-05-05 Akeso Biopharma, Inc. Anti-tigit antibody, and pharmaceutical composition and use thereof
EP4240415A1 (en) 2020-11-08 2023-09-13 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022111612A1 (zh) * 2020-11-26 2022-06-02 信达生物制药(苏州)有限公司 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
IL307556A (en) 2021-04-09 2023-12-01 Seagen Inc Cancer treatment methods using antibodies against TIGIT
WO2022214652A1 (en) 2021-04-09 2022-10-13 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
US20240182571A1 (en) 2021-04-09 2024-06-06 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
KR20230160389A (ko) 2021-04-22 2023-11-23 광동 파폰 바이오파마 인크. 이중 특이성 다기능 융합 폴리펩티드
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
CA3219603A1 (en) * 2021-05-10 2022-11-17 Medimabbio Inc. Anti-tigit antibodies and use thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
AU2022314097A1 (en) * 2021-07-23 2024-03-07 Akeso Biopharma, Inc Pharmaceutical composition and use
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CN116284390A (zh) * 2021-12-21 2023-06-23 广东安普泽生物医药股份有限公司 人tigit抗体及其应用
WO2023149977A1 (en) * 2022-02-04 2023-08-10 Mereo Biopharma 5, Inc. Methods for treating cancer
JP2025509832A (ja) 2022-03-15 2025-04-11 コンピュジェン リミテッド Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
JP2025516262A (ja) 2022-05-02 2025-05-27 アーカス バイオサイエンシズ インコーポレイティド 抗ｔｉｇｉｔ抗体及びその使用
WO2023234748A1 (ko) * 2022-06-03 2023-12-07 메디맵바이오 주식회사 항-tigit 항체 및 이의 용도
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025002151A1 (zh) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 抗tigit抗体及其应用
WO2025016012A1 (en) * 2023-07-14 2025-01-23 Genor Biopharma Co., Ltd. Anti-PD-1/CTLA-4/TIGIT TRISPECIFIC ANTIBODIES AND USE THEREOF
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050809A1 (en) 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
CU23007A1 (es) 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
ES2357505T3 (es) 2002-09-11 2011-04-27 Genentech, Inc. Composición y procedimientos novedosos para el tratamiento de enfermedades inmunorelacionadas.
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20070054360A1 (en) 2005-05-12 2007-03-08 Zeren Gao Compositions and methods for modulating immune responses
AU2006308847C1 (en) 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
MX2010011088A (es) * 2008-04-09 2010-11-05 Genentech Inc Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
US8551715B2 (en) 2010-02-12 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for identifying and isolating cells expressing a polypeptide
BR112013021473A2 (pt) 2011-02-23 2020-08-04 F. Hoffmann-La Roche Ag anticorpos contra il33r humano e seus usos
EP2785375B1 (en) * 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
US9327014B2 (en) 2012-12-04 2016-05-03 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
CN103073644B (zh) 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
DK3021869T3 (da) * 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
WO2016011264A1 (en) 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
KR102050082B1 (ko) 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
SG10202006538TA (en) 2014-12-23 2020-08-28 Bristol Myers Squibb Co Antibodies to tigit
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10766957B2 (en) 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
AU2016322934A1 (en) 2015-09-14 2018-04-12 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
IL261188B (en) 2016-03-04 2022-08-01 Jn Biosciences Llc An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents

Also Published As

Publication number Publication date
SI3303379T1 (sl) 2022-01-31
CA2987607A1 (en) 2016-12-01
CN115429877A (zh) 2022-12-06
AU2016267577B2 (en) 2020-12-10
AU2016267577A1 (en) 2017-12-21
WO2016191643A2 (en) 2016-12-01
CN109071620B (zh) 2022-05-10
HUE057087T2 (hu) 2022-04-28
ES2902150T3 (es) 2022-03-25
PT3303379T (pt) 2022-01-06
IL255577A (en) 2018-01-31
EP3303379A2 (en) 2018-04-11
JP6875295B2 (ja) 2021-05-19
WO2016191643A3 (en) 2017-01-12
WO2016191643A4 (en) 2017-03-23
HRP20211948T1 (hr) 2022-03-18
US20190077864A1 (en) 2019-03-14
RS62815B1 (sr) 2022-02-28
KR20180014050A (ko) 2018-02-07
JP7203446B2 (ja) 2023-01-13
JP2018521634A (ja) 2018-08-09
MA42622A (fr) 2018-06-20
US10544219B2 (en) 2020-01-28
US20160376365A1 (en) 2016-12-29
CO2017012342A2 (es) 2018-02-28
LT3303379T (lt) 2021-12-10
US10112997B2 (en) 2018-10-30
NZ738008A (en) 2019-08-30
MX2017014955A (es) 2018-04-13
DK3303379T3 (da) 2021-12-06
MA42622B1 (fr) 2021-11-30
IL255577B (en) 2022-02-01
EP3303379B1 (en) 2021-10-13
SA517390370B1 (ar) 2021-09-12
KR102721641B1 (ko) 2024-10-25
MD3303379T2 (ro) 2022-02-28
EP3303379A4 (en) 2019-04-17
BR112017025529A2 (en) 2018-08-07
CY1125260T1 (el) 2023-03-24
EP4011907A1 (en) 2022-06-15
PL3303379T3 (pl) 2022-02-07
ZA201708265B (en) 2025-04-30
CL2017003021A1 (es) 2018-06-01
TWI715587B (zh) 2021-01-11
JP2021118719A (ja) 2021-08-12
CN109071620A (zh) 2018-12-21
SMT202100711T1 (it) 2022-01-10
ECSP17083779A (es) 2018-02-28
TW201718646A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
MX384199B (es) Agentes de union a inmunorreceptor de celulas t con dominios ig y motivo de inhibicion basado en tirosina de inmunorreceptor (tigit) y usos de los mismos.
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CL2020003031A1 (es) Agentes aglutinantes del psma y usos de estos.
MX2018005546A (es) Anticuerpos que se unen especificamente a pd-1 y tim-3 y sus usos.
MX393066B (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
CR20170079A (es) Agentes de unión a cd123 y usos de estos
MX2016012880A (es) Cadena j modificada.
UY36974A (es) Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas
MX2020006585A (es) Anticuerpos que se unen a ctla-4 y usos de los mismos.
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
CO2017010618A2 (es) Anticuerpos contra icos
MX2016009555A (es) Proteinas de union y metodos para utilizarlas.
MX2017015042A (es) Anticuerpos cd123 y conjugados de los mismos.
UY40672A (es) “ANTICUERPOS AISLADOS BIESPECÍFICOS GPRC5D x CD3 Y COMPOSICIONES QUÍMICAS QUE LOS CONTIENEN”
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
MX2018003196A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
CO2020006453A2 (es) Anticuerpos anti-cxcr5 y composiciones y usos de los mismos
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
MX380601B (es) Proteínas de unión a cd33 y cd3 biespecíficas.
CR20170109A (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
CO2017003005A2 (es) Anticuerpos anti-mfi2
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.